The primary outcome measure is instrumental activities of daily living measured using the Nottingham Extended Activities of Daily Living scale (NEADL) as activities of daily living (ADL) is the target of the intervention. Secondary outcomes are: health-related quality of life (Parkinson's Disease Questionnaire 39, PDQ-39; EuroQol EQ-5D), cost-effectiveness (cost per quality adjusted life year), adverse events and carer quality of life (Carer Short Form 12, SF12). Outcomes were assessed before randomisation and by post at 3, 9 and 15 months post randomisation.